{
  "guideline": {
    "id": "PA166122806",
    "name": "Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B",
    "source": "CPIC",
    "version": 51,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166122806",
    "relatedChemicals": [
      {
        "id": "PA164746820",
        "name": "fosphenytoin",
        "symbol": null
      },
      {
        "id": "PA450947",
        "name": "phenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      },
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298422",
      "name": "Recommendation PA166298422",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061024,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298435",
      "name": "Recommendation PA166298435",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061037,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298382",
      "name": "Recommendation PA166298382",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060984,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298440",
      "name": "Recommendation PA166298440",
      "population": "PHT use >3mos",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061042,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298409",
      "name": "Recommendation PA166298409",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061011,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298369",
      "name": "Recommendation PA166298369",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060971,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298431",
      "name": "Recommendation PA166298431",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061033,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298399",
      "name": "Recommendation PA166298399",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061001,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298417",
      "name": "Recommendation PA166298417",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061019,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298364",
      "name": "Recommendation PA166298364",
      "population": "PHT naive",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060966,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298377",
      "name": "Recommendation PA166298377",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060979,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298408",
      "name": "Recommendation PA166298408",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061010,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298395",
      "name": "Recommendation PA166298395",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060997,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298400",
      "name": "Recommendation PA166298400",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061002,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298413",
      "name": "Recommendation PA166298413",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061015,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298360",
      "name": "Recommendation PA166298360",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060962,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298426",
      "name": "Recommendation PA166298426",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061028,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298373",
      "name": "Recommendation PA166298373",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060975,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298439",
      "name": "Recommendation PA166298439",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061041,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298386",
      "name": "Recommendation PA166298386",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060988,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298404",
      "name": "Recommendation PA166298404",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061006,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298432",
      "name": "Recommendation PA166298432",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061034,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298392",
      "name": "Recommendation PA166298392",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060994,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298410",
      "name": "Recommendation PA166298410",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061012,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298423",
      "name": "Recommendation PA166298423",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061025,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298370",
      "name": "Recommendation PA166298370",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060972,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298379",
      "name": "Recommendation PA166298379",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060981,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298441",
      "name": "Recommendation PA166298441",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061043,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298387",
      "name": "Recommendation PA166298387",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060989,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298405",
      "name": "Recommendation PA166298405",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061007,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298418",
      "name": "Recommendation PA166298418",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061020,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298365",
      "name": "Recommendation PA166298365",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060967,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298378",
      "name": "Recommendation PA166298378",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060980,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298383",
      "name": "Recommendation PA166298383",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060985,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298436",
      "name": "Recommendation PA166298436",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061038,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298401",
      "name": "Recommendation PA166298401",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061003,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298396",
      "name": "Recommendation PA166298396",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060998,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298361",
      "name": "Recommendation PA166298361",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060963,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298414",
      "name": "Recommendation PA166298414",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061016,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298427",
      "name": "Recommendation PA166298427",
      "population": "PHT use >3mos",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061029,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298374",
      "name": "Recommendation PA166298374",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060976,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298420",
      "name": "Recommendation PA166298420",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061022,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298433",
      "name": "Recommendation PA166298433",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061035,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298393",
      "name": "Recommendation PA166298393",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060995,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298411",
      "name": "Recommendation PA166298411",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061013,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298367",
      "name": "Recommendation PA166298367",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060969,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298442",
      "name": "Recommendation PA166298442",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061044,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298375",
      "name": "Recommendation PA166298375",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060977,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298388",
      "name": "Recommendation PA166298388",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060990,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298406",
      "name": "Recommendation PA166298406",
      "population": "PHT naive",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061008,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298419",
      "name": "Recommendation PA166298419",
      "population": "PHT naive",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061021,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298366",
      "name": "Recommendation PA166298366",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060968,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298424",
      "name": "Recommendation PA166298424",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061026,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298371",
      "name": "Recommendation PA166298371",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060973,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298437",
      "name": "Recommendation PA166298437",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061039,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298384",
      "name": "Recommendation PA166298384",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060986,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298402",
      "name": "Recommendation PA166298402",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061004,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298397",
      "name": "Recommendation PA166298397",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060999,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298362",
      "name": "Recommendation PA166298362",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060964,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298359",
      "name": "Recommendation PA166298359",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060961,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298421",
      "name": "Recommendation PA166298421",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061023,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298434",
      "name": "Recommendation PA166298434",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061036,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298381",
      "name": "Recommendation PA166298381",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060983,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298394",
      "name": "Recommendation PA166298394",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060996,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298368",
      "name": "Recommendation PA166298368",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060970,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298430",
      "name": "Recommendation PA166298430",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061032,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298390",
      "name": "Recommendation PA166298390",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060992,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298363",
      "name": "Recommendation PA166298363",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060965,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298429",
      "name": "Recommendation PA166298429",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061031,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298376",
      "name": "Recommendation PA166298376",
      "population": "PHT naive",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060978,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298389",
      "name": "Recommendation PA166298389",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060991,
        "html": "<p>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298407",
      "name": "Recommendation PA166298407",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061009,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal phenytoin metabolism",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298412",
      "name": "Recommendation PA166298412",
      "population": "PHT naive",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061014,
        "html": "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: Increased risk of phenytoin-induced SJS/TEN"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298372",
      "name": "Recommendation PA166298372",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060974,
        "html": "<p>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298425",
      "name": "Recommendation PA166298425",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061027,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298438",
      "name": "Recommendation PA166298438",
      "population": "PHT use >3mos",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061040,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298385",
      "name": "Recommendation PA166298385",
      "population": "PHT use >3mos",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060987,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298403",
      "name": "Recommendation PA166298403",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061005,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298398",
      "name": "Recommendation PA166298398",
      "population": "PHT use >3mos",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061000,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298416",
      "name": "Recommendation PA166298416",
      "population": "PHT naive",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061018,
        "html": "<p>For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.</p>\n"
      },
      "implications": [
        "CYP2C9: Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
        "HLA-B: n/a"
      ],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "32779747",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.",
      "authors": [
        "Karnes Jason H",
        "Rettie Allan E",
        "Somogyi Andrew A",
        "Huddart Rachel",
        "Fohner Alison E",
        "Formea Christine M",
        "Ta Michael Lee Ming",
        "Llerena Adrian",
        "Whirl-Carrillo Michelle",
        "Klein Teri E",
        "Phillips Elizabeth J",
        "Mintzer Scott",
        "Gaedigk Andrea",
        "Caudle Kelly E",
        "Callaghan John T"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2021
    },
    {
      "pmid": "25099164",
      "title": "Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.",
      "authors": [
        "Caudle K E",
        "Rettie A E",
        "Whirl-Carrillo M",
        "Smith L H",
        "Mintzer S",
        "Lee M T M",
        "Klein T E",
        "Callaghan J T",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2014
    }
  ],
  "version": "2024-03-25-16-13"
}